The duration dilemma in opioid agonist therapy

Anjali Dhanda, MD; Edwin A. Salsitz, MD, DFASAM

doi:10.5055/jom.2021.0668

Authors

Anjali Dhanda, MD
Edwin A. Salsitz, MD, DFASAM

DOI:

https://doi.org/10.5055/jom.2021.0668

Keywords:

opioid agonist therapy, opioid maintenance treatment duration, methadone maintenance treatment, buprenorphine maintenance treatment

Abstract

Objective: Studies dating back to 1964 consistently support the effectiveness of methadone as a maintenance treatment for opioid use disorder (OUD), and since 2003, the effectiveness of buprenorphine. Short-term detoxification has not proven to be an effective treatment, as it results in high relapse rates when compared with maintenance treatment with an opioid agonist therapy (OAT). The question about the duration of maintenance treatment for OUD has been debated with recommendations ranging from a minimum of 1 year, 2 years, to indefinitely. Other factors such as misconceptions, regulations, and insurance barriers also have an impact on the duration dilemma of OAT.

Design: There were no a priori criteria for article inclusion and this is not a structured literature review. It is a review of articles of convenience from 1964 to 2018.

Main outcome measure: This paper aims to address the dilemma of the ideal duration of OAT and to discuss the factors that could affect this decision.

Results: Sustained OAT has had significantly better long-term outcomes than short-term detoxification or time limited maintenance. Optimal outcomes are dependent on adequate treatment duration.

Conclusions: Addiction is a chronic brain disease and its treatment should be similar to the treatment of other chronic medical and psychiatric diseases. Long-term, sometimes lifetime, continuation of OAT for the treatment of OUD results in optimal outcomes when measuring morbidity and mortality. The accumulated evidence does not support any arbitrary limitation to the duration of OAT.

Author Biographies

Anjali Dhanda, MD

Cornell Scott Hill Health Center, Ansonia, Connecticut

Edwin A. Salsitz, MD, DFASAM

Psychiatry, Division of Chemical Dependency, Mount Sinai Beth Israel, New York City, New York

References

Krebs E, Enns B, Evans E, et al.: Cost-effectiveness of publicly funded treatment of opioid use disorder in California. Ann Intern Med. 2018; 168(1): 10. DOI: 10.7326/M17-0611.

Tetrault JM, Fiellin DA: More beds or more chairs? Using a science-based approach to address the opioid epidemic. Ann Intern Med. 2018; 168(1): 73. DOI: 10.7326/M17-2854.

Sordo L, Barrio G, Bravo MJ, et al.: Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies. BMJ. 2017; 357: j1550. DOI: 10.1136/bmj.j1550.

Degenhardt L, Charlson F, Mathers B, et al.: The global epidemiology and burden of opioid dependence: Results from the global burden of disease 2010 study. Addiction. 2014; 109(8): 1320-1333. DOI: 10.1111/add.12551.

Heather MO, Justin JL, Maulik B, et al.: Original quantitative research—Canadian trends in opioid-related mortality and disability from opioid use disorder from 1990 to 2014 through the lens of the Global Burden of Disease Study. Health Promot Chronic Dis Prev Can. 2018; 38(6): 234-243.

Fiellin DA, Schottenfeld RS, Cutter CJ, et al.: Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: A randomized clinical trial. JAMA Intern Med. 2014; 174(12): 1947. DOI: 10.1001/jamainternmed.2014.5302.

Hser Y-I, Saxon AJ, Huang D, et al.: Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial: Treatment retention on buprenorphine/methadone. Addiction. 2014; 109(1): 79-87. DOI: 10.1111/add.12333.

Bentzley BS, Barth KS, Back SE, et al.: Discontinuation of buprenorphine maintenance therapy: Perspectives and outcomes. J Sub Abuse Treat. 2015; 52: 48-57. DOI: 10.1016/j.jsat.2014.12.011.

Manhapra A, Rosenheck R, Fiellin DA: Opioid substitution treatment is linked to reduced risk of death in opioid use disorder. BMJ. 2017; 357: j1947. DOI: 10.1136/bmj.j1947.

McLellan AT, Lewis DC, O’Brien CP, et al.: Drug dependence, a chronic medical illness: Implications for treatment, insurance, and outcomes evaluation. JAMA. 2000; 284(13): 1689. DOI: 10.1001/jama.284.13.1689.

Sees KL, Delucchi KL, Masson C, et al.: Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: A randomized controlled trial. JAMA. 2000; 283(10): 1303. DOI: 10.1001/jama.283.10.1303.

Kakko J, Svanborg KD, Kreek MJ, et al.: 1-Year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: A randomised, placebo-controlled trial. Lancet. 2003; 361(9358): 662-668. DOI: 10.1016/S0140-6736(03)12600-1.

Weiss RD, Potter JS, Griffin ML, et al.: Long-term outcomes from the national drug abuse treatment clinical trials network prescription opioid addiction treatment study. Drug Alcohol Depend. 2015; 150: 112-119. DOI: 10.1016/j.drugalcdep.2015.02.030.

Hser Y-I, Hoffman V, Grella CE, et al.: A 33-year follow-up of narcotics addicts. Arch Gen Psychiatry. 2001; 58(5): 503. DOI: 10.1001/archpsyc.58.5.503.

Leshner AI: Addiction is a brain disease, and it matters. Science. 1997; 278(5335): 45-47. DOI: 10.1126/science.278.5335.45.

National consensus development panel on effective medical treatment of opiate addiction. Effective medical treatment of opiate addiction. JAMA. 1998; 280(22): 1936-1943. DOI: 10.1001/jama.280.22.1936.

The Surgeon General's Report | Surgeon General's Report on Alcohol, Drugs, and Health. Available at https://addiction.surgeongeneral.gov/executive-summary/report. Accessed October 28, 2019.

Duvall HJ, Locke BZ, Brill L: Followup study of narcotic drug addicts five years after hospitalization. Public Health Rep. 1963; 78(3): 185-194.

Hunt GH, Odoroff ME: Followup study of narcotic drug addicts after hospitalization. Public Health Rep. (1896–1970). 1962; 77(1): 41. DOI: 10.2307/4591408.

Ball JC, Lange WR, Myers CP, et al.: Reducing the risk of AIDS through methadone maintenance treatment. J Health Soc Behav. 1988; 29(3): 214-226.

Grönbladh L, Öhlund LS, Gunne LM: Mortality in heroin addiction: Impact of methadone treatment. Acta Psychiatry Scand. 1990; 82(3): 223-227. DOI: 10.1111/j.1600-0447.1990.tb03057.x.

Kaufman MJ, Pollack MH, Villafuerte RA, et al.: Cerebral phosphorus metabolite abnormalities in opiate-dependent polydrug abusers in methadone maintenance. Psychiatry Res. 1999; 90(3): 143-152. DOI: 10.1016/s0925-4927(99)00017-7.

Langleben DD, Ruparel K, Elman I, et al.: Acute effect of methadone maintenance dose on brain FMRI response to heroin-related cues. Am J Psychiatry. 2008; 165(3): 390-394. DOI: 10.1176/appi.ajp.2007.07010070.

Novick DM, Richman BL, Friedman JM, et al.: The medical status of methadone maintenance patients in treatment for 11–18 years. Drug Alcohol Depend. 1993; 33(3): 235-245. DOI: 10.1016/0376-8716(93)90110-C.

Cotton BP, Bryson WC, Bruce ML: Methadone maintenance treatment for older adults: Cost and logistical considerations. Psychiatr Serv. 2018; 69(3): 338-340. DOI: 10.1176/appi.ps.201700137.

Dürsteler-MacFarland KM, Vogel M, Wiesbeck GA, et al.: There is no age limit for methadone: A retrospective cohort study. Subst Abuse Treat Prev Policy. 2011; 6: 9. DOI: 10.1186/1747-597X-6-9.

Committee Opinion No. 524: Opioid abuse, dependence, and addiction in pregnancy. Obstet Gynecol. 2012; 119(5): 1070-1076. DOI: 10.1097/AOG.0b013e318256496e.

Bagley SM, Wachman EM, Holland E, et al.: Review of the assessment and management of neonatal abstinence syndrome. Addict Sci Clin Pract. 2014; 9(1): 19. DOI: 10.1186/1940-0640-9-19.

Joseph H, Stancliff S, Langrod J: Methadone maintenance treatment (MMT): A review of historical and clinical issues. Mt Sinai J Med. 2000; 67(5-6): 347-364.

Bell J, Towers CV, Hennessy MD, et al.: Detoxification from opiate drugs during pregnancy. Am J Obstet Gynecol. 2016; 215(3): 374.e1-374.e6. DOI: 10.1016/j.ajog.2016.03.015.

Jones HE, Jansson LM, O’Grady KE, et al.: The relationship between maternal methadone dose at delivery and neonatal outcome: Methodological and design considerations. Neurotoxicol Teratol. 2013; 39: 110-115. DOI: 10.1016/j.ntt.2013.05.003.

Jones HE, Fischer G, Heil SH, et al.: Maternal opioid treatment: Human experimental research (MOTHER)-approach, issues and lessons learned: MOTHER project. Addiction. 2012; 107: 28-35. DOI: 10.1111/j.1360-0443.2012.04036.x.

Farid W, Dunlop S, Tait R, et al.: The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: Review of human and animal data. Curr Neuropharmacol. 2008; 6(2): 125-150. DOI: 10.2174/157015908784533842.

Hadland SE, Park TW, Bagley SM. Stigma associated with medication treatment for young adults with opioid use disorder: A case series. Addict Sci Clin Pract. 2018; 13(1): 15. DOI: 10.1186/s13722-018-0116-2.

Bentzley BS, Barth KS, Back SE, et al.: Patient perspectives associated with intended duration of buprenorphine maintenance therapy. J Subst Abuse Treat. 2015; 56: 48-53. DOI: 10.1016/j.jsat.2015.04.002.

Singer M, Bulled N, Ostrach B, et al.: Syndemics and the biosocial conception of health. Lancet. 2017; 389(10072): 941-950. DOI: 10.1016/S0140-6736(17)30003-X.

Novick DM: Methadone maintenance patients in general medical practice: A preliminary report. JAMA. 1988; 259(22): 3299. DOI: 10.1001/jama.1988.03720220045024.

Center for Substance Abuse Treatment. Medication-Assisted Treatment for Opioid Addition in Opioid Treatment Programs. Rockville, MD: HHS Publication No. (SMA) 08-4214, 2005.

Novick DM: Absence of antibody to human immunodeficiency virus in long-term, socially rehabilitated methadone maintenance patients. Arch Intern Med. 1990; 150(1): 97. DOI: 10.1001/archinte.1990.00390130099014.

Bojko MJ, Mazhnaya A, Marcus R, et al.: The future of opioid agonist therapies in Ukraine: A qualitative assessment of multilevel barriers and ways forward to promote retention in treatment. J Sub Abuse Treat. 2016; 66: 37-47. DOI: 10.1016/j.jsat.2016.03.003.

Wakeman SE: Using science to battle stigma in addressing the opioid epidemic: Opioid agonist therapy saves lives. Am J Med. 2016; 129(5): 455-456. DOI: 10.1016/j.amjmed.2015.12.028.